TYP tryptamine therapeutics limited

Ann: Exopharm Gains US Patent for LEAP Technology, page-4

  1. 2,992 Posts.
    lightbulb Created with Sketch. 79
    What did BB say that isn’t true? He’s not down ramping or starting an argument. He’s speaking the truth as a shareholder.

    Ex1 has been a massive disappointment in terms of shareprice since the second last capital raise. They over promised and have under delivered. If you look at the shareprice chart and think it hasn’t been a disappointment then we’re on different planets.

    They need to do what they said they were close to a long time ago, land a deal.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
3.1¢
Change
0.000(0.00%)
Mkt cap ! $43.06M
Open High Low Value Volume
3.1¢ 3.1¢ 3.1¢ $9.612K 310.0K

Buyers (Bids)

No. Vol. Price($)
3 302229 3.0¢
 

Sellers (Offers)

Price($) Vol. No.
3.1¢ 1013 1
View Market Depth
Last trade - 12.21pm 16/07/2025 (20 minute delay) ?
TYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.